Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

Oligometastases: the art of providing metastases-directed therapy in prostate cancer

Nature Reviews Urology volume 19, pages 259–260 (2022)Cite this article

Subjects

Prostate-specific membrane antigen-targeted positron emission tomography has revolutionized prostate cancer diagnostics and holds the potential to advance metastases-directed therapy through, among other treatments, ablative radiotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Weichselbaum, R. R. & Hellman, S. Oligometastases revisited. Nat. Rev. Clin. Oncol. 8, 378–382 (2011).

    Article  CAS  Google Scholar 

  2. Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395, 1208–1216 (2020).

    Article  CAS  Google Scholar 

  3. Mazonne, E. et al. Diagnostic value, oncologic outcomes, and safety profile of image-guided surgery technologies during robot-assisted lymph node dissection with sentinel node biopsy for prostate cancer. J. Nucl. Med. 62, 1363–1371 (2021).

    Article  Google Scholar 

  4. Horn, T. et al. Single lesion on prostate-specific membrane antigen-ligand positron emission tomography and low prostate-specific antigen are prognostic factors for a favorable biochemical response to prostate-specific membrane antigen-targeted radioguided surgery in recurrent prostate cancer. Eur. Urol. 76, 517–523 (2019).

    Article  CAS  Google Scholar 

  5. Mazzola, R. et al. Metastasis-directed therapy (SBRT) guided by PET-CT 18F-choline versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness. Clin. Genitourin. Cancer 19, 230–236 (2021).

    Article  Google Scholar 

  6. Hölscher, T. et al. Toxicity and efficacy of local ablative, image-guided radiotherapy in gallium-68 prostate-specific membrane antigen targeted positron emission tomography–staged, castration-sensitive oligometastatic prostate cancer: the OLI-P phase 2 clinical trial. Eur. Urol. Oncol. https://doi.org/10.1016/j.euo.2021.10.002 (2021).

    Article  PubMed  Google Scholar 

  7. Lehrer, E. J. et al. Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis. JAMA Oncol. 7, 92–106 (2021).

    Article  Google Scholar 

  8. Steuber, T. et al. Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study. Eur. Urol. Focus 5, 1007–1013 (2019).

    Article  CAS  Google Scholar 

  9. Ost, P. et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J. Clin. Oncol. 36, 446–453 (2018).

    CAS  Google Scholar 

  10. Phillips, R. et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 6, 650–659 (2020).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, Netherlands

    Fijs W. B. van Leeuwen

  2. Department of Urology, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

    Fijs W. B. van Leeuwen & Henk G. van der Poel

Authors
  1. Fijs W. B. van Leeuwen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henk G. van der Poel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fijs W. B. van Leeuwen.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

SABR-COMET: https://clinicaltrials.gov/ct2/show/NCT01446744

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van Leeuwen, F.W.B., van der Poel, H.G. Oligometastases: the art of providing metastases-directed therapy in prostate cancer. Nat Rev Urol 19, 259–260 (2022). https://doi.org/10.1038/s41585-022-00570-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-022-00570-9

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing